

Healthcare systems will be required to submit updates to the appropriate quality measure(s) below at three intervals throughout the project, paying careful attention to the reporting and measurement periods. Healthcare systems will report combined results for all clinics participating in the project. Please note these data definitions are subject to change.

HPV VACCINATION QUALITY MEASURE DESCRIPTION

ELIGIBLE PATIENTS (DENOMINATOR)

Include adolescents aged 9-13 with at least one reportable medical visit during the trailing 12-month measurement period. Group eligible patients using the following age ranges: 9-10, 11-12, and 13. You may separate by sex or report combined. See exclusions below. This denominator will be used for all HPV, meningococcal, and tdap measures.

Exclusions

- Exclude dental or other non-medical visits. Medical visits *do* include well-child visits and sick visits.
- Exclude patients who were screened, tested, or vaccinated for COVID-19 without an accompanying medical exam or treatment. A COVID-19 test or screening alone does not count as a reportable medical visit.

HPV VACCINATION INITIATION QUALITY MEASURE DESCRIPTION

Percentage of adolescents 9-13 years of age who started the HPV vaccine series. You may separate by sex or report combined. Group eligible patients using the following age ranges: 9-10, 11-12, and 13.

NUMERATOR: ELIGIBLE PATIENTS WHO STARTED THE HPV VACCINE SERIES (≥1 dose)

- Include eligible patients who have *ever received* at least one dose of the HPV vaccine.
- Include eligible patients who have *also received their 2nd dose*.
- Include eligible patients who have received doses of the vaccine *even if it was before the project period*.

HPV VACCINATION COMPLETION QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 9-13 who completed the HPV vaccine series. You may separate by sex or report combined. Group eligible patients using the following age ranges: 9-10, 11-12, and 13.

NUMERATOR: ELIGIBLE PATIENTS WHO COMPLETED THE HPV VACCINE SERIES (2 doses)

- Include eligible patients who have *ever received* two doses of the HPV vaccine separated by at least 5 months.
- Include eligible patients who have received doses of the vaccine *even if it was before the project period*.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- If reporting sex separately, group patients according to assigned sex at birth.
- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- This information should be accessed via a EHR or population health system. For information on manual chart audits, please contact your American Cancer Society team member.

MENINGOCOCCAL CONJUGATE QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 11-13 who have received the meningococcal conjugate (MenACWY) vaccine. You may separate by sex or report combined. Group eligible patients using the following age ranges: 11-12, and 13.

NUMERATOR: ELIGIBLE PATIENTS WHO HAVE RECEIVED THE MENINGOCOCCAL VACCINE

- Include eligible patients who have ever received the meningococcal conjugate vaccine. See exclusions below.

Exclusions

- Exclude Meningococcal B vaccines from calculation.

TDAP QUALITY MEASURE DESCRIPTION

Percentage of adolescents ages 11-13 who received the Tdap vaccine. You may separate by sex or report combined. Group eligible patients using the following age ranges: 11-12, and 13.

NUMERATOR: ELIGIBLE PATIENTS WHO HAVE RECEIVED THE TDAP VACCINE

- Include eligible patients who have *ever received* the Tdap vaccine.

ADDITIONAL GUIDANCE

- Only eligible patients included in the denominator should be included in the numerator.
- If reporting sex separately, group patients according to assigned sex at birth.
- Only eligible patients included in the denominator should be included in the numerator.
- Only include information for clinics participating in the project.
- This information should be accessed via a EHR or population health system. For information on manual chart audits, please contact your American Cancer Society team member.